Therapeutic potential of novel Cell Division Cycle Kinase 7 inhibitors on TDP‐43‐related pathogenesis such as Frontotemporal Lobar Degeneration (FTLD) and amyotrophic lateral sclerosis (ALS)
Gabriela Liseth Vaca-Altamirano(Centro de Investigaciones Biológicas Margarita Salas), Ángeles Martín‐Requero(Centro de Investigación Biomédica en Red), Loreto Martínez‐González(Consejo Superior de Investigaciones Científicas), Ana Martı́nez(Consejo Superior de Investigaciones Científicas), Carmen Gil(Instituto de Salud Carlos III), Elisa Rojas‐Prats(Centro de Investigaciones Biológicas Margarita Salas), Gracia Porras(Centro de Investigaciones Biológicas Margarita Salas), Ana Fernández(Centro de Investigaciones Biológicas Margarita Salas), Eva P. Cuevas(Centro de Investigación Biomédica en Red)
Cited by 30
Related Papers
COVID-19: Drug Targets and Potential Treatments
|Journal of Medicinal Chemistry|2020|469
First Non-ATP Competitive Glycogen Synthase Kinase 3 β (GSK-3β) Inhibitors: Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer's Disease
|Journal of Medicinal Chemistry|2002|448
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS
|Frontiers in Molecular Neuroscience|2011|348
Glycogen synthase kinase 3 (GSK‐3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation
|Medicinal Research Reviews|2002|334
TNFα disrupts blood brain barrier integrity to maintain prolonged depressive-like behavior in mice
|Brain Behavior and Immunity|2018|293